| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于注销首次公开发行股票募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、首次公开发行股票募集资金基本情况 三、首次公开发行股票募集资金专项账户销户情况 2024 年 5 月 13 日，经公司 2023 年年度股东大会审议通过，公司结合自身经 营情况、公司战略规划梳理及募集资金使用效率等因素，终止募投项目全厂节能 节水减排绿色发展综合升级改造项目，将结余的募集资金 12,963.95 万元及募集 资金账户利息收入 1,527.47 万元用于永久补充流动资金。 经中国证券监督管理委员会《关于核准浙江华康药业股份有限公司首次公开 发行股票的批复》（证监许可[2020]3152 号）核准，并经上海证券交易所同意， 公司首次公开发行人民币普通股 A 股股票 2,914 万股，每股发行价格为人民 ...

Group 1 - The core viewpoint of the news is that Huakang Co., Ltd. has seen a significant increase in its stock price, rising by 5.28% to 18.35 CNY per share, with a total market capitalization of 5.561 billion CNY [1] - Huakang Co., Ltd. specializes in the research, production, and sales of various functional sugar alcohols and starch sugar products, with its main business revenue composition being 54.36% from crystalline sugar alcohol products, 32.46% from liquid sugars and alcohols, and 13.18% from other products [1] - The company is located in Kaifa County, Zhejiang Province, and was established on July 10, 2001, with its listing date on February 9, 2021 [1] Group 2 - From the perspective of fund holdings, one fund under Wan Jia Fund has a significant position in Huakang Co., Ltd., with the Wan Jia Quantitative Tongshun A fund holding 44,000 shares, accounting for 0.98% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Quantitative Tongshun A fund has a total scale of 28.1768 million CNY and has achieved a year-to-date return of 16.29%, ranking 4630 out of 8162 in its category [2] - The fund has a one-year return of 30.77%, ranking 2195 out of 8024, and a cumulative return since inception of 49.82% [2]

Core Viewpoint - The company is entering a production phase for its "1 million tons corn deep processing health food ingredients project," which is expected to impact its revenue and profit structure due to changes in product mix and rising management costs [1] Group 1: Project Updates - The first phase of the "1 million tons corn deep processing health food ingredients project" is entering production, focusing on liquid syrup and some crystalline sugar alcohol products [1] - The second phase of the "200 million tons corn deep processing health food ingredients project" is planned for future development, with various product lines to be constructed at an appropriate time [1] Group 2: Financial Performance - The gross margin has decreased primarily due to changes in the sales product structure caused by the launch of production lines at Zhoushan Huakang [1] - Management expenses are expected to rise in 2024 due to increased employee compensation related to the Zhoushan project and higher stock-based compensation expenses from the company's equity incentive plan [1] Group 3: Growth Drivers - The company's xylitol, crystalline sorbitol, and crystalline maltitol products are leading in market capacity and output, which will continue to be the main sources of revenue and profit [1]

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 累计转股情况：浙江华康药业股份有限公司（以下简称"公司"）本次 发行的"华康转债"自 2024 年 7 月 1 日起可转换为本公司股份。截至 2025 年 9 月 30 日，累计人民币 804,000 元"华康转债"转换成公司股份，占可转债发行 总量的 0.0617%；转股数量为 47,631 股，占可转债转股前公司发行股份总额 （304,989,880 股）的 0.0156%。 本季度转股情况：自 2025 年 7 月 1 日至 2025 年 9 月 30 日，共有人民币 26,000 元"华康转债"已转换成公司股份，占可转债发行总量的 0.0020%；转股 数量为 1,577 股，占可转债转股前公司发行股份总额（3 ...

1、基本情况 2022 年，浙江华康药业股份有限公司以 21,976,440 元人民币认购宁波中药 制药股份有限公司（以下简称"宁波中药"）定向发行股票 8,518,000 股，并与 宁波中药签署《股票认购合同》、与宁波中药控股股东及实际控制人方明先生签 署《股票认购合同之补充协议》。具体内容详见公司于 2022 年 1 月 8 日、2 月 8 日、3 月 11 日、5 月 24 日在上海证券交易所网站（http://www.sse.com.cn）发 布的《华康股份关于拟认购宁波中药制药股份有限公司定向发行股票的公告》 （2022-001）、《华康股份关于认购宁波中药制药股份有限公司定向发行股票的 进展公告》（2022-005）、《华康股份关于认购宁波中药制药股份有限公司定向 发行股票的进展公告》（2022-010）、《华康股份关于认购宁波中药制药股份有 限公司定向发行股票的进展公告》（2022-035）。 根据《股票认购合同》的业绩承诺及补偿条款，宁波中药因 2022 年、2023 年考核期未能完成考核指标，方明先生无偿向公司转让其持有的宁波中药 1,362,880 股股份作为补偿。截至目前，公司持有宁波中 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 10 月 10 日(星期五)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 " 路 演 中 心 " （ 网 址 ： https://roadshow.sseinfo.com/） 本公司董事长、总经理陈德水先生，财务负责人汪家发先生，董事会秘书吴 志平先生，独立董事李军先生。（如有特殊情况，参会人员可能进行调整） 浙江华康药业股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2025 年半年度报告，为加强与 投资者的深入交流，公司拟以网络互动的方式召开 ...

Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

Core Viewpoint - The announcement details the adjustment of the conversion price for the company's convertible bonds due to the implementation of a profit distribution plan for the first half of 2025, resulting in a decrease in the conversion price from 16.46 CNY to 16.26 CNY per share [2][3][6]. Group 1: Conversion Price Adjustment - The initial conversion price of the "Huakang Convertible Bonds" was set at 22.66 CNY per share, which has undergone several adjustments due to various corporate actions [5]. - The conversion price was adjusted to 16.89 CNY per share on May 28, 2024, and further adjusted to 16.39 CNY on April 24, 2025, before the latest adjustment [5]. - The new conversion price of 16.26 CNY per share will take effect on September 29, 2025, following the distribution of a cash dividend of 0.2 CNY per share [3][6]. Group 2: Profit Distribution Plan - The company plans to distribute a cash dividend of 0.2 CNY per share, amounting to a total of approximately 6,060.99622 million CNY based on the total share capital of 30,304.9811 million shares [11][13]. - The profit distribution plan was approved during the second extraordinary general meeting of shareholders held on September 8, 2025 [11]. - The distribution will be executed through the Shanghai Clearing House, with specific procedures outlined for both unrestricted and restricted shareholders [14][16].

浙江华康药业股份有限公司 关于因实施权益分派调整"华康转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因实施 2025 年半年度权益分派，本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 111018 | 华康转债 | 可转债转股复牌 | | | 2025/9/26 | 2025/9/29 | 一、转股价格调整依据 | 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 二、转股价格历次调整情况 本次发行可转换公司债券"华康转债"的初始转股价格为 22.66 元/股。历次转股 价格调整情况如下： 因公司实施 2023 年度权益分派，"华康转债"转 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码:111018 | 债券简称:华康转债 | | 浙江华康药业股份有限公司 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/26 | － | 2025/9/29 | 2025/9/29 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 9 月 8 日的2025年第二次临时股东大会审议 通过。 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.2元 相关日期 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司" ...